The Role of Natural Killer, Complement and T-lymphocytes in COVID-19 Disease, a Prospective Monocentric Study

NCT05258643 | Unknown DMC

• 1 other identifier: 2020/177
• Study Type: interventional
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

The current study is an open, non-randomized, monocentric, and interventional study. CoViD-19 patients will be recruited at UZ Brussel after informed consent is obtained. Whole blood and serum samples will be collected during acute disease (inclusion and 7 days after inclusion) and during patient follow-up at 2 months after infection. Sample storage and subsequent use in fundamental research will be performed at VUB Neuro-Aging and Viro-Immunotherapy. Additionally, medical records of UZ Brussel will be searched and epidemiological, clinical, radiological, and biological data of the selected patients will be obtained at the diagnosis time point and during follow-up. Healthy volunteers will be recruited as well in the current study, as a comparison arm, after informed consent is obtained.

Conditions

Complement Abnormality; Peripheral Blood Mononuclear Cells; Covid19

Outcome Measures

Primary Outcomes (1)

• Difference in complements or peripheral blood mononuclear cells between CoViD-19 patients and controls

  up to 1 year

Study Arms (2)

Covid-19 patients

OTHER

Whole blood and serum samples will be collected during acute disease (inclusion and 7 days after inclusion) and during patient follow-up at 2 months after infection

Other: Blood analysis

Controle

OTHER

Whole blood and serum samples will be collected during the same period

Other: Blood analysis

Interventions

Blood analysis OTHER

Venipuncture and collection of serum and whole blood

Controle; Covid-19 patients

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Positive nasopharyngeal reverse transcriptase-polymerase chain reaction for SARS-Coronavirus-02
• Signed inform consent
• Healthy Volunteers
• Signed inform consent

Sponsors & Collaborators

• Universitair Ziekenhuis Brussel: lead

Study Sites (1)

UZ Brussel

Jette, Brussels Capital, 1090, Belgium

RECRUITING

MeSH Terms

Conditions

COVID-19

Interventions

Hematologic Tests

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Investigative Techniques

Study Officials

• Sabine Allard, PhD

  UZ Brussel (Vrije Universiteit Brussel)

  STUDY DIRECTOR

• Joeri Aerts, PhD

  Vrije Universiteit Brussel

  STUDY CHAIR

Central Study Contacts

Marco Moretti

CONTACT

+32 (0)2477 6001; marco.moretti@uzbrussel.be

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 3, 2021
• First Posted: February 28, 2022
• Study Start: September 1, 2020
• Primary Completion: May 1, 2024
• Study Completion: September 1, 2024
• Last Updated: February 28, 2022

Record last verified: 2021-04

Locations

BE (1)